Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12417-12421

  Chiang, Jessica J ^a   Gardner, Matthew R ^a   Quinlan, Brian D ^a   Dorfman, Tatyana ^a   Choe, Hyeryun ^b   Farzan, Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCR5 MIMETIC PEPTIDE 1; CCR5 MIMETIC PEPTIDE 1 IMMUNOGLOBULIN; CD4 IMMUNOGLOBULIN; CHEMOKINE RECEPTOR CCR5; CHIMERIC PROTEIN; ENVELOPE PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN; PEPTIDOMIMETIC AGENT; PROTEIN CDR3; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CHIMERA; CONCENTRATION RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; SULFATION; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; GLYCOPROTEINS; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CCR5;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869106867     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00967-12     Document Type: Article

References (24)

1. Choe H, et al. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
2. Choe H, et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114:161-170.
3. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953-8957.
4. Cormier EG, et al. 2000. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 97:5762-5767.
5. Dalgleish AG, et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767.
6. Dorfman T, Moore MJ, Guth AC, Choe H, Farzan M. 2006. A tyrosinesulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem. 281:28529-28535.
7. Farzan M, et al. 2002. The role of post-translational modifications of the CXCR4 amino-terminus in stromal-derived factor 1 alpha association and HIV-1 entry. J. Biol. Chem. 277:29484-29489.
8. Farzan M, et al. 1998. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72:1160-1164.
9. Farzan M, et al. 1999. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667-76.
10. Farzan M, et al. 2000. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J. Biol. Chem. 275:33516-33521.
11. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
12. Huang CC, et al. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934.
13. Johnson PR, et al. 2009. Vector-mediated gene transfer engenders longlived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:901-906.
14. Kwong JA, et al. 2011. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein. J. Virol. 85:7563-7571.
15. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
16. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
17. McCarty DM. 2008. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16:1648-1656.
18. Moebius U, Clayton LK, Abraham S, Harrison SC, Reinherz EL. 1992. The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J. Exp. Med. 176:507-517.
19. Rizzuto CD, et al. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
20. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-4422.
21. Trkola A, et al. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
22. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
23. Wu L, et al. 1996. CD4-induced interactions of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 184:179-183.
24. Wyatt R, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.